Smith & Nephew Pursues “Lifetime” Implant
The board of directors of Irvine, Calif.-based Pro-Dex Inc. named Richard L.Van Kirk as CEO, effective immediately. He succeeds Harold A.
Hurwitz, who served as the company’s
CEO since February 2013 and chief financial officer (CFO) since October 2010. In
addition, Alisha Charlton has been appointed CFO, also effective immediately.
Van Kirk, 54, joined the company as director of manufacturing in 2006, and was
subsequently promoted to vice president
of operations and then chief operating officer in April 2013. He previously served
as manufacturing manager and manager
of product development for the Charge-Source division of Comarco, Inc., and as
general manager at Dynacast.
Charlton, 45, joined the company in
January 2014 as senior director of finance.
Prior to joining Pro-Dex, Charlton held
various accounting positions at Comarco
Inc. from 2000 culminating in her appointment as chief accounting officer in
April 2011. Prior to her 13-year tenure at
Comarco, Charlton held various accounting and finance positions with CKE Restaurants Inc. from 1995 to 2000. She began
her career in 1991 with KPMG Peat Mar-wick (now KPMG LLP) and formerly was
a certified public accountant.
Nick Swenson, chairman of the com-
pany’s board noted, “The board has confi-
dence that Rick’s leadership style will drive
growth and profitability at Pro-Dex. Rick
is an experienced leader and his knowl-
edge of Pro-Dex gives him the know-how
to rapidly move the business forward.”
Swenson thanked Hurwitz for his four
years of service.
“Hal’s leadership brought stability to
the company during a time of significant
change and challenge,” Swenson said.
“His thoughtful leadership contributed
importantly to our new product develop-
ment processes, which we expect to bear
fruit in coming quarters.”
“I am grateful and excited by the op-
portunity to lead the Pro-Dex organiza-
tion, its management team and employ-
ees,” said Van Kirk. “Together, with the
support of our board, I am looking forward
to launching our new products, integrat-
ing our acquisitions and driving growth.”
Pro-Dex, with operations in California
and Oregon, specializes in the design, de-
velopment and manufacture of powered
rotary drive surgical and dental instruments
used primarily in the orthopedic, spine,
maxocranial facial and dental markets.
Editor’s note: Van Kirk also has penned regular columns for Orthopedic Design & Technology magazine.
Bone Solutions Names New CEO
Dallas, Texas-based Bone Solutions Inc.
has appointed a new CEO. Drew M. Diaz
has worked in the healthcare field for
more than 27 years, most recently serving
five years as co-founder and CEO of Heart
Test Laboratories Inc., a U.S. cardiology
device company. Prior to Heart Test Laboratories, Diaz was senior vice president of
global sales for Criticare Systems Inc., a
U.S. manufacturer of anesthesia, cardiac
and patient monitoring equipment. He
has held positions with various Fortune
500 companies, including IBM, Pfizer, and
DeRoyal Industries throughout his career.
Diaz has experience and knowledge of
domestic and international medical device
management in addition to a deep understanding of development and strategic
planning of medical exports, according to
the company. Well versed in international
trade and management, Diaz has managed offices in Brazil, China, Germany,
India, and the United States. As the managing director and president of Medical
Logistics GmbH, a medical device company in Bad Homburg Germany, Diaz was
responsible for the administration, engineering, technical support and all sales
Diaz is a board member of three medical organizations in the United States. He
is a graduate of Texas A&M University and
has attended Harvard University Business
School Executive Training.
“We are extremely proud to announce
a president of Drew Diaz’s caliber and expertise” said Tom Lally, founder and executive chairman of Bone Solutions Inc.
InVivo Therapeutics Appoints Board
Chairman, Chief Medical Officer
Cambridge, Mass.-based InVivo Therapeutics Holdings Corp. has appointed
Mark D. Perrin as chairman of its board of
directors, effective immediately. Perrin has
served as a board member and CEO of the
company since January 2014. John A. McCarthy, Jr., current non-executive chairman of the board since September 2013,
will remain on the board and will continue
to chair the audit committee.
“I look forward to taking on the chal-
lenges of board chair,” Perrin said. “We all
appreciate John’s broad input and exper-
tise, and we know his support for InVivo’s
future will be important as we move ahead
with the Neuro-Spinal Scaffold and other
The company also has appointed Lo-
rianne Masuoka, M.D., as chief medical
officer (CMO), effective March 2. She will
be taking over for the interim CMO, Lou
Vaickus, M.D., who is also founder and
president of Akta Pharmaceutical Develop-
ment LLC, a life sciences consulting firm.
Prior to joining the InVivo team, Masuoka served as senior vice president and
chief medical officer at Cubist Pharmaceuticals from July 2013 until Jan 2015. As
a member of Cubist’s executive management team, she managed over 150 employees in the areas of clinical research,
drug safety, biostatistics and data management, and clinical operations. Prior to
her time at Cubist, she served in various
roles of increasing responsibility at Nek-
Pro-Dex Names New CEO